Pacific Biosciences of California Director Acquires $687,939 in Stock (PACB)
Pacific Biosciences of California (NASDAQ:PACB) Director William W. Ericson acquired 135,155 shares of the stock on the open market in a transaction dated Monday, August 18th. The shares were purchased at an average cost of $5.09 per share, for a total transaction of $687,938.95. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Pacific Biosciences of California (NASDAQ:PACB) opened at 4.96 on Friday. Pacific Biosciences of California has a 1-year low of $3.32 and a 1-year high of $8.20. The stock’s 50-day moving average is $5.1 and its 200-day moving average is $5.46. The company’s market cap is $350.3 million.
Pacific Biosciences of California (NASDAQ:PACB) last posted its quarterly earnings results on Thursday, July 24th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by $0.12. The company had revenue of $11.40 million for the quarter, compared to the consensus estimate of $11.39 million. During the same quarter in the previous year, the company posted ($0.33) earnings per share. The company’s revenue for the quarter was up 90.0% on a year-over-year basis. Analysts expect that Pacific Biosciences of California will post $-1.07 EPS for the current fiscal year.
Pacific Biosciences, Inc develops Deoxyribonucleic Acid (NASDAQ:PACB) sequencing platform.
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with Analyst Ratings Network's FREE daily email newsletter.